The Sulforaphane and pyridoxamine supplementation normalize endothelial dysfunction associated with type 2 diabetes

Area of Science:

• Biochemistry
• Endocrinology
• Pharmacology

Background:

• Type 2 diabetes is characterized by oxidative stress and endothelial dysfunction.
• NFE2-related factor 2 (Nrf2) activators and advanced glycation end products (AGE) inhibitors are potential therapeutic targets.

Purpose of the Study:

• To investigate pyridoxamine (PM) and sulforaphane (SFN) as therapeutic interventions for type 2 diabetes.
• To determine if Nrf2 activators combined with AGE formation inhibitors can reduce oxidative stress and improve endothelial dysfunction.

Main Methods:

• Goto-kakizaki (GK) rats, a model for type 2 diabetes, were treated with PM and/or SFN for 8 weeks.
• Vascular reactivity, metabolic profile, nitric oxide (NO) bioavailability, oxidative stress, AGE, and Nrf2 levels were assessed.

Main Results:

• Diabetic GK rats showed lower Nrf2 levels, higher oxidative stress, and endothelial dysfunction.
• PM and SFN monotherapies improved endothelial dysfunction, reduced oxidative damage, AGE, and HbA1c.
• Combination therapy (SFN + PM) was more effective in reducing free fatty acids, normalizing endothelial function, NO bioavailability, and glycation.

Conclusions:

• Nrf2 activators can be therapeutically combined with AGE formation inhibitors.
• This combined approach can normalize endothelial dysfunction in type 2 diabetes.
• PM and SFN demonstrate potential as therapeutic agents for managing type 2 diabetes complications.